NICE began appraising the GLP-1 pill for NHS use in England and Wales
Awaiting primary-source check
A NICE committee was due to meet in July 2026 to consider orforglipron, the once-daily oral non-peptide GLP-1, for NHS use in England and Wales. The appraisal follows the drug's US approval on 1 April 2026 and runs in parallel with the MHRA's own licensing decision, which has not yet been made. Published phase 3 figures from ATTAIN-1 reported weight reduction of 7.5 per cent, 8.4 per cent and 11.2 per cent across three dose levels over 72 weeks, against 2.1 per cent on placebo, in a trial funded by Eli Lilly.
What this actually means
A NICE appraisal starting is not the same as a drug becoming available, and the sequence trips people up constantly.
Two separate things have to happen. The MHRA decides whether the drug can be sold in the UK at all. NICE decides whether the NHS pays for it. Running the appraisal in parallel is deliberate and saves time, but it means neither decision has been made yet.
On the numbers, note the honest comparison: 11.2 per cent at the top dose is less than tirzepatide achieves, and tirzepatide is already licensed and available here. The case for a pill is access, cost and manufacturing scale, not maximum effect. If NICE says yes, expect strict eligibility criteria, because that is how every drug in this class has arrived on the NHS so far.
Told first, next time
This story reached you late. A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.